Here's Won't Touch Teva: Why I Pass on the Generic Giant
Teva Pharmaceuticals sits at a crossroads of debt, generics, and a shifting pricing landscape. Here's why I won't tou...
Learn the long-term average annual return for index funds and how it informs portfolio construction, diversification, and risk management.
27,739 articlesTeva Pharmaceuticals sits at a crossroads of debt, generics, and a shifting pricing landscape. Here's why I won't tou...
JPMorgan CEO Jamie Dimon dismissed Donald Trump’s $5 billion debanking lawsuit as meritless, but said he understands ...
Vanguard’s FTSE Developed Markets ETF has posted stronger gains than the S&P 500 in 2026, drawing renewed investor in...
Nvidia faces strong AI-driven demand and a robust roadmap that could push long-term targets higher. Analysts weigh ne...
Bitcoin briefly topped $80,000 again as traders weigh whether the move signals real demand or a looming reversal. Ana...
This guide decodes MKSI's 2026 earnings call, explaining what to watch, how management guidance shapes strategy, and ...
A nationwide $1 million cap on home equity for Medicaid long-term care applicants will reshape eligibility rules and ...
U.S. stocks pulled back on February 27, 2026, with the S&P 500 slipping roughly 0.8% as technology led declines and s...
The White House has tapped a real-estate heir as acting director of national intelligence, a move that drew sharp que...
A Senate staff brief on the ROAD to Housing Act flags design flaws and local zoning reliance, signaling lenders and b...
U.S. stocks fell sharply as fears of broader conflict intensified. The S&P 500 dropped about 1% in early trading, wit...
U.S. stocks climb as a fresh wave of analyst upgrades targets blue-chip names and high-growth plays. Here Tuesday’s W...